Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people

Abstract

BackgroundCurcumin extracts of turmeric are proposed to produce health benefits. To date, human intervention studies have focused mainly on people with existing health problems given high doses of poorly absorbed curcumin. The purpose of the current study was to check whether in healthy people, a low dose of a lipidated curcumin extract could alter wellness-related measures.MethodsThe present study was conducted in healthy middle aged people (40–60 years old) with a low dose of curcumin (80 mg/day) in a lipidated form expected to have good absorption. Subjects were given either curcumin (N = 19) or placebo (N = 19) for 4 wk. Blood and saliva samples were taken before and after the 4 weeks and analyzed for a variety of blood and saliva measures relevant to health promotion.ResultsCurcumin, but not placebo, produced the following statistically significant changes: lowering of plasma triglyceride values, lowering of salivary amylase levels, raising of salivary radical scavenging capacities, raising of plasma catalase activities, lowering of plasma beta amyloid protein concentrations, lowering of plasma sICAM readings, increased plasma myeloperoxidase without increased c-reactive protein levels, increased plasma nitric oxide, and decreased plasma alanine amino transferase activities.ConclusionCollectively, these results demonstrate that a low dose of a curcumin-lipid preparation can produce a variety of potentially health promoting effects in healthy middle aged people.

Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer’s disease

“…Initially, several commercially available curcumin brands were analyzed for their absorption into the blood and brain, and the ratios of curcumin concentrations in the brain and red blood cells (RBCs) were determined in wild-type mice (Supplemental Figure 4). The highest brain concentrations were obtained with Longvida Optimized Curcumin formulation coated with lipophilic matrix (74,75) (Supplemental Figure 4). The optimal curcumin formulation, dose, and regimen were further calibrated through in vivo retinal amyloid imaging in double-transgenic APP SWE /PS1 ΔE9 mouse models (Supplemental Figure 5).…”

“…Curcumin showed a distinct labeling pattern that was similar to the amyloid spots observed in living patients. Curcumin is considered as generally recognized as safe by the FDA based on previous clinical trials (74,75,104), and the Longvida curcumin used in this study caused minimal to no adverse effects. Longvida's safety has been demonstrated in pharmacokinetic studies in humans (105) and extensive toxicity testing in animals (106), and its efficacy has been demonstrated in two clinical trials (74,75).…”

“…Curcumin is considered as generally recognized as safe by the FDA based on previous clinical trials (74,75,104), and the Longvida curcumin used in this study caused minimal to no adverse effects. Longvida's safety has been demonstrated in pharmacokinetic studies in humans (105) and extensive toxicity testing in animals (106), and its efficacy has been demonstrated in two clinical trials (74,75). The choice of curcumin as an amyloid contrast agent in living patients was further supported by the experiments presented here ( Figure 6 and Supplemental Figures 4-5 and 7), previously in vivo and ex vivo in ADtg mice (40,51), and in a study using OCT imaging in MCI patients (107).…”

Curcumin Modulates Molecular Chaperones and Autophagy-Lysosomal Pathways In Vitro after Exposure to Aβ42

“…This SLCP consists of high-purity, long-chain phospholipid bilayer and a long-chain fatty acid solid lipid core, which coats the Cur. The SLCP have been well characterized by Maiti et al [34] and by Cole and Frautschy laboratory, at the University of California, Los Angeles in collaboration with Verdure Science [26,[35][36][37]. Details sources of all the antibodies used in this study are summarized in Table 1.…”

Anti-Inflammatory Effects of Novel Standardized Solid Lipid Curcumin Formulations

“…26 In addition, DiSilvestro et al demonstrated that a low dose of Longvida (80 mg/day) imparted potentially healthpromoting effects in healthy middle-aged humans. 27 In addition, in a recent investigation, Longvida selectively suppressed soluble Tau dimers and corrected molecular chaperone, synaptic, and behavioral deficits in transgenic mice, suggesting that this curcumin formulation may have potential beneficial effects against Alzheimer's disease. 28 However, to date, the effects of this bioavailable curcumin preparation, namely, Longvida, on inflammation and inflammatory biomarkers remain unknown.…”